At the 2025 Kidney Cancer Research Summit, Dr. Berkay Simsek highlighted the potential role of tumor-associated macrophages (TAMs) in predicting responses to PD-1 inhibitors in metastatic clear cell kidney cancer cases. TAMs, a type of immune cell infiltrating tumors, have varying impacts on cancer treatment efficacy depending on the cancer type. While they are often associated with treatment resistance in some cancers like colorectal and pancreatic cancers, in Hodgkin lymphoma, they have shown a correlation with improved treatment responses. However, their predictive role in clinical outcomes in metastatic clear cell renal cell carcinoma (ccRCC) remains ambiguous.
Dr. Simsek’s study delved into the influence of CD163-positive TAMs on the effectiveness of first-line PD-1 immunotherapy, particularly with Opdivo (nivolumab). His findings suggest that high levels of these specific TAMs might be reprogrammed during treatment to shift from supporting tumor growth to aiding the immune system in combating the cancer cells. Moreover, his research explored the interactions between TAMs and other immune cells within specific regions of tumors, emphasizing the significance of analyzing these interactions in pretreatment samples to potentially identify patients who are more likely to benefit from immunotherapy.
Immunotherapy’s target is not the tumor itself but the immune cells present in the tumor microenvironment. Different immunotherapies target distinct markers on these immune cells, necessitating a comprehensive understanding of which immune cells express these markers. Analyzing the composition of the tumor microenvironment, particularly in pretreatment samples, and correlating it with outcomes such as progression-free survival and response rate, plays a crucial role in refining the selection of patients eligible for immunotherapy. By deciphering which immune cells express key markers and how these expressions relate to clinical outcomes, researchers can advance the precision and efficacy of immunotherapy administration.
Key Takeaways:
– Tumor-associated macrophages (TAMs) may have a predictive role in determining responses to PD-1 inhibitors in metastatic clear cell kidney cancer.
– High levels of CD163-positive TAMs could potentially be reprogrammed during immunotherapy to enhance the immune system’s ability to combat cancer cells.
– Understanding the interactions between TAMs and other immune cells within tumors, especially in pretreatment samples, is crucial for identifying patients who are likely to benefit from immunotherapy.
– Analyzing the composition of the tumor microenvironment and its correlation with clinical outcomes like progression-free survival can aid in refining patient selection for immunotherapy interventions.
Tags: immunotherapy
Read more on curetoday.com